Kinesin mutations may disrupt organelle transport, putting motor neurons at risk.
What goes up can come down—rising tides of VILIP-1, neurogranin, and SNAP-25 ebb after onset of AD symptoms.
A large, prospective study confirms that PD unfolds more slowly in people with the G2019S LRRK2 mutation. The data will help scientists design and interpret clinical trials.
The knock-ins had no motor deficits or TDP-43 cytoplasmic inclusion. Instead, the animals had FTD-like behavioral problems.
A family of petite, RNA-directed nucleases offers a platform for finessing the transcriptome.
Rush University researcher recognized for longitudinal studies on aging, memory, and dementia.
Researchers report a link between sleepiness and accelerated Aβ buildup in the cingulate and precuneus of elderly adults without dementia.
Voyager Therapeutics announced positive interim results from a small, ongoing Phase 1b trial in people with advanced PD.
Representing each cell as a point, the atlas could help scientists measure brain-wide cell numbers and activity in health and disease.
Two new papers strengthen the evidence that TREM2 protects against amyloid pathology.
A winter storm cut the meeting short, but not before attendees learned that viral load correlates with clinical and pathological traits of AD.
A CRISPR knockout screen in human cells and mouse neurons found genes that tweak C9ORF72 toxicity, zeroing in on ER stress as a potential therapeutic target.
After verubecestat’s demise, scientists ask if BACE inhibitor side effects could partly stem from the other BACE.
In transgenic mice, killing off microglia with the CSF1R inhibitor PLX3397 prevented accumulation of intraneuronal Aβ, neuritic plaques.
World’s biggest brain research award goes to European leaders on Aβ tau and TREM2.